BR112015000685A2 - método para a identificação de risco clínico em um paciente possuindo ou suspeito de possuir uma infecção por influenza, método para a identificação de influenza ou pneumonia viral em um paciente, kit, método para avaliar a eficácia de um agente para o tratamento de influenza e para reduzir a severidade da doença em um indivíduo exposto a um vírus influenza. - Google Patents

método para a identificação de risco clínico em um paciente possuindo ou suspeito de possuir uma infecção por influenza, método para a identificação de influenza ou pneumonia viral em um paciente, kit, método para avaliar a eficácia de um agente para o tratamento de influenza e para reduzir a severidade da doença em um indivíduo exposto a um vírus influenza.

Info

Publication number
BR112015000685A2
BR112015000685A2 BR112015000685A BR112015000685A BR112015000685A2 BR 112015000685 A2 BR112015000685 A2 BR 112015000685A2 BR 112015000685 A BR112015000685 A BR 112015000685A BR 112015000685 A BR112015000685 A BR 112015000685A BR 112015000685 A2 BR112015000685 A2 BR 112015000685A2
Authority
BR
Brazil
Prior art keywords
influenza
identifying
patient
suspected
assessing
Prior art date
Application number
BR112015000685A
Other languages
English (en)
Inventor
Mclean Anthony
Tang Benjamin
Shojaei Maryam
Grant Parnell Peter
Original Assignee
Nepean Blue Mountains Local Health Distr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2012902954A external-priority patent/AU2012902954A0/en
Application filed by Nepean Blue Mountains Local Health Distr filed Critical Nepean Blue Mountains Local Health Distr
Publication of BR112015000685A2 publication Critical patent/BR112015000685A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6851—Quantitative amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/11—Orthomyxoviridae, e.g. influenza virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
BR112015000685A 2012-07-10 2013-07-10 método para a identificação de risco clínico em um paciente possuindo ou suspeito de possuir uma infecção por influenza, método para a identificação de influenza ou pneumonia viral em um paciente, kit, método para avaliar a eficácia de um agente para o tratamento de influenza e para reduzir a severidade da doença em um indivíduo exposto a um vírus influenza. BR112015000685A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2012902954A AU2012902954A0 (en) 2012-07-10 Risk stratification in influenza
PCT/AU2013/000765 WO2014008545A1 (en) 2012-07-10 2013-07-10 Risk stratification in influenza

Publications (1)

Publication Number Publication Date
BR112015000685A2 true BR112015000685A2 (pt) 2017-11-28

Family

ID=49915252

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015000685A BR112015000685A2 (pt) 2012-07-10 2013-07-10 método para a identificação de risco clínico em um paciente possuindo ou suspeito de possuir uma infecção por influenza, método para a identificação de influenza ou pneumonia viral em um paciente, kit, método para avaliar a eficácia de um agente para o tratamento de influenza e para reduzir a severidade da doença em um indivíduo exposto a um vírus influenza.

Country Status (10)

Country Link
US (2) US10036075B2 (pt)
EP (1) EP2872891B1 (pt)
JP (1) JP6097388B2 (pt)
KR (1) KR20150040289A (pt)
CN (1) CN104769430B (pt)
AU (1) AU2013289854B2 (pt)
BR (1) BR112015000685A2 (pt)
CA (1) CA2877400A1 (pt)
DK (1) DK2872891T3 (pt)
WO (1) WO2014008545A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015103664A1 (en) * 2014-01-09 2015-07-16 Nepean Blue Montains Local Health District Risk stratification in influenza
WO2016024278A1 (en) 2014-08-14 2016-02-18 Memed Diagnostics Ltd. Computational analysis of biological data using manifold and a hyperplane
EP3146974A1 (en) 2015-09-25 2017-03-29 Universite Claude Bernard - Lyon 1 Biomarkers for early determination of severity of influenza related disease
US11466331B2 (en) 2016-03-03 2022-10-11 Memed Diagnostics Ltd. RNA determinants for distinguishing between bacterial and viral infections
WO2017149547A1 (en) 2016-03-03 2017-09-08 Memed Diagnostics Ltd. Analyzing rna for diagnosing infection type
CN109661578B (zh) 2016-07-10 2022-05-10 米密德诊断学有限公司 用于区分细菌和病毒感染的蛋白质特征
EP4184167A1 (en) 2016-07-10 2023-05-24 MeMed Diagnostics Ltd. Early diagnosis of infections
US20210230694A1 (en) * 2018-06-05 2021-07-29 University Of Rochester Nasal genes used to identify, characterize, and diagnose viral respiratory infections

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5792626A (en) * 1996-09-18 1998-08-11 Incyte Pharmaceuticals, Inc. Human interferon-inducible protein
US6821724B1 (en) * 1998-09-17 2004-11-23 Affymetrix, Inc. Methods of genetic analysis using nucleic acid arrays
US7214498B2 (en) * 2001-03-23 2007-05-08 Benaroya Research Institute At Virginia Mason Tumor associated antigens and methods of using the same
JP2004121218A (ja) * 2002-08-06 2004-04-22 Jenokkusu Soyaku Kenkyusho:Kk 気管支喘息または慢性閉塞性肺疾患の検査方法
WO2005068664A2 (en) * 2004-01-09 2005-07-28 The Regents Of The University Of California Cell-type-specific patterns of gene expression
US20050244851A1 (en) * 2004-01-13 2005-11-03 Affymetrix, Inc. Methods of analysis of alternative splicing in human
WO2007034280A2 (en) * 2005-09-19 2007-03-29 Moshe Amihood Blay Composition and method for prevention of influenza
CN101541976A (zh) * 2006-08-11 2009-09-23 贝勒研究院 利用血液白细胞中的基因表达标记物的急性感染的鉴别诊断
CN102112878A (zh) * 2008-06-06 2011-06-29 国立大学法人富山大学 用于检测流感病毒的装置
WO2010076788A2 (en) * 2008-12-29 2010-07-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods of predicting responsiveness to interferon treatment and treating hepatitis c infection
WO2011008349A2 (en) * 2009-05-26 2011-01-20 Duke University Methods of identifying infectious disease and assays for identifying infectious disease
EP2451476A4 (en) * 2009-07-06 2013-07-03 Alnylam Pharmaceuticals Inc BIOTRAITEMENT BASED ON CELLS
US20120214705A1 (en) * 2009-09-28 2012-08-23 The Regents Of The University Of California Office of Technology, Beta-defensin 2 genetic variation predicts h. pylori susceptibility
WO2013030841A1 (en) * 2011-09-04 2013-03-07 Yissum Research Development Company Of The Hebrew Universitiy Of Jerusalem Ltd. Prognostic methods and compositions for predicting interferon treatment eficacy in a subject

Also Published As

Publication number Publication date
CA2877400A1 (en) 2014-01-16
JP6097388B2 (ja) 2017-03-15
AU2013289854A2 (en) 2015-02-26
DK2872891T3 (da) 2019-05-13
US10036075B2 (en) 2018-07-31
EP2872891A1 (en) 2015-05-20
AU2013289854B2 (en) 2016-03-24
JP2015530868A (ja) 2015-10-29
CN104769430A (zh) 2015-07-08
EP2872891A4 (en) 2016-01-20
WO2014008545A1 (en) 2014-01-16
US20150322538A1 (en) 2015-11-12
CN104769430B (zh) 2018-12-14
EP2872891B1 (en) 2019-03-13
US20180298455A1 (en) 2018-10-18
AU2013289854A1 (en) 2015-01-22
KR20150040289A (ko) 2015-04-14

Similar Documents

Publication Publication Date Title
BR112015000685A2 (pt) método para a identificação de risco clínico em um paciente possuindo ou suspeito de possuir uma infecção por influenza, método para a identificação de influenza ou pneumonia viral em um paciente, kit, método para avaliar a eficácia de um agente para o tratamento de influenza e para reduzir a severidade da doença em um indivíduo exposto a um vírus influenza.
BR112015003397A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente.
BR112017018944A2 (pt) método de tratamento de um estado ou condição de doença em humanos com um medicamento carbinóide, e, método de tratamento de um estado ou condição de doença em um mamífero diferente de um humano com medicamento(s) carbinóide(s)
BR112014018331A8 (pt) Biomarcadores e terapias combinadas usando vírus oncolítico e imunomodulação
BR112015003332A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BR112015003398A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BR112015009636A8 (pt) composto, métodos para o tratamento de um hospedeiro infectado, métodos para a prevenção de uma infecção, métodos para a redução da atividade biológica de uma infecção e uso de um composto
AR090465A1 (es) Formas solidas de un profarmaco de nucleotidos de tiofosforamidato
BR112017024929A2 (pt) conjugados de oligonucleotídeo-peptídeo
BR112013024574A2 (pt) polipeptídeo, uso, método de tratamento de indivíduos portadores de doenças e método de tratamento de indivíduos que possuem doenças com um polipeptídeo
BR112015002524A2 (pt) derivados de alquilpirimidina para o tratamento de infecções virais e outras doenças.
BR112013020425A2 (pt) composições e métodos para o tratamento ou prevenção de infecção por vírus da hepatite b
BR112013020352A2 (pt) composto, composição farmacêutica, uso de um composto e método para tratar doença ou condição mediana por rorgamat num indivíduo
AR091316A1 (es) Moleculas de union humanas que se pueden unir y neutralizar a los virus de la influenza b y sus usos
CU23938B1 (es) Moléculas de unión humanas capaces de neutralizar el virus de la influenza h3n2
BR112014002614A2 (pt) anticorpo ou um fragmento do mesmo, que tem reatividade imunológica com uma proteína caprin-1, composição farmacêutica e combinação farmacêutica para tratamento e/ou prevenção de câncer, dna e método para tratamento e/ou prevenção de câncer
BR112014004181A2 (pt) composto, composição farmacêutica, e, método de tratamento, prevenção, e / ou retardo do início de uma doença ou patologia
CL2012002606A1 (es) Composicion farmaceutica que comprende (-)-carvona, (+)-carvona, trans-geraniol y al menos un componente elegido de aceites esenciales para uso en el tratamiento y prevencion de enfermedades virales.
BR112015007758A2 (pt) dispositivo para um tratamento médico de uma esclera, método para tratar a esclera em um sujeito e método para tratar uma alteração patológica ou doença do olho.
BR112014025339A8 (pt) método para tratamento ou prevenção ou redução de infecção do virus influenza e composição farmacêutica para o mesmo.
BR112015017241A2 (pt) doadores de nitroxil com índice terapêutico melhorado
BR112012002001A2 (pt) método para tratar uma doença e/ou distúrbio do olho, formulação farmacêutica, e, kit
BR112016028446A2 (pt) inibidor de complemento de ornithodoros moubata para uso no tratamento de doenças mediadas por complemento em pacientes com polimorfismo de c5
BR112014020885A2 (pt) oligonucleotídeos para modulação da expressão gênica e seu uso
BR112014021927A2 (pt) composição farmacêutica antirretroviral, processo para preparar uma composição farmacêutica antirretroviral, método para o tratamento ou profilaxia de doenças causadas por retrovírus, e, uso de lamivudina, festinavir e nevirapina

Legal Events

Date Code Title Description
B06U Preliminary requirement: requests with searches performed by other patent offices: suspension of the patent application procedure
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements